title: Early psychosis in Asia: Insights from Japan.
abstract: The largest task for psychiatry in Japan today is the deinstitutionalization of patients with psychiatric disorders. In Japan, all citizens are covered by a national health plan, and about 70% of the total cost is covered by the national health insurance scheme. At present, however, there is still no category for early intervention in the national health reimbursement schedule. Recent research has shown that the mean duration of untreated psychosis (DUP) at seven university hospitals in Japan was 17.6 months. We present data using case vignettes suggesting that pharmacotherapy might be overused in prodromal cases. The concept of an At-Risk Mental State (ARMS)/prodromal state might not yet be widely recognized among Japanese psychiatrists. We outline early intervention initiatives in Japan; The Japanese Society for Prevention and Early Intervention in Psychiatry (JSEIP), and a representative early intervention facility for young people is the "Il Bosco" in Tokyo. There are several leading centers for early intervention research and practice in Japan. Most of them are driven by university departments of psychiatry with respect to both research and clinical activities. The development of services for early intervention is expected to reduce stigmatization, prevent suicide among young persons, and promote general knowledge about mental health. There are several common or similar issues among Asian countries, including service systems, community attitudes to psychiatric illness including stigma, and dependence on pharmacotherapy.
authors.affiliation: Department of Neuropsychiatry, Toho University School of Medicine, 6-11-1, Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Mizuno
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nemoto
authors.forename: Naohisa
authors.initials: N
authors.lastname: Tsujino
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Funatogawa
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Takeshi
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D061345:Early Medical Intervention / Q000191:economics / Q000706:statistics & numerical data*; D006801:Humans; D007564:Japan; D008605:Mental Health Services; D009313:National Health Programs / Q000191:economics; D010818:Practice Patterns, Physicians'; D062706:Prodromal Symptoms; D011570:Psychiatry; D011618:Psychotic Disorders / Q000191:economics / Q000628:therapy*; D012559:Schizophrenia / Q000191:economics / Q000628:therapy*; D057545:Social Stigma; D013240:Stereotyping; D013405:Suicide; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents